1. Scrip
  2. >>R&D
  3. >>Clinical Trials

Newron Points ‘Future Value-Driver’ Evenamide At Drug-Resistant Schizophrenia

Following Phase II Promise

 
• By Ayisha Sharma

The Italian firm’s VGSC-blocker has demonstrated long-term symptom improvement in a mid-stage trial in drug-resistant schizophrenia, expediting Phase III development plans that could help address a high unmet need.  

One head split into two faces, one red and one blue, representing concept of schizophrenia
Schizophrenia Affects Around 24 Million People Worldwide • Source: Shutterstock

Newron Pharmaceuticals S.p.A.’s evenamide has shown signs of long-term safety and efficacy as an add-on therapy in a Phase II treatment-resistant schizophrenia (TRS) trial, sparking the advancement of pivotal development for the key value driver.

Evenamide blocks voltage-gated sodium channels (VGSCs), which is theorized to normalize glutamate release induced by aberrant sodium channel activity without affecting basal glutamate levels

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

Pipeline Watch: Six Approvals And Thirteen Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Viatris Will File ‘Fast-Acting’ Meloxicam For FDA Approval This Year

 
• By Joseph Haas

Seven years after acquiring it, Viatris will seek approval of a meloxicam formulation for acute pain backed by data from two Phase III studies in post-surgical pain settings.

CRISPR Therapeutics Unveils Promising Early In Vivo Cholesterol-Lowering Results

 
• By Andrew McConaghie

The Phase I results are the best to date among ANGPTL3-targeting candidates in the pipeline, but analysts will wait for further updates before predicting a likely winner.

Sanofi R&D Head’s Words Of Wisdom For Biotechs

 
• By Kevin Grogan

Houman Ashrafian tells delegates at Swiss Biotech Day that ‘literally only two things matter in our industry – target credentialing and differentiated pharmacology. The rest is execution.’

More from R&D

Sanofi R&D Head’s Words Of Wisdom For Biotechs

 
• By Kevin Grogan

Houman Ashrafian tells delegates at Swiss Biotech Day that ‘literally only two things matter in our industry – target credentialing and differentiated pharmacology. The rest is execution.’

Marea Eyes Cardioprotective Benefit With ANGPTL4 Inhibition

 
• By Joseph Haas

Phase IIa data for ANGPTL4-targeted antibody shows reduced triglycerides and remnant cholesterol, which Marea asserts indicates potential to protect against cardiovascular outcomes.

First Win For AstraZeneca’s Enhertu In Early-Stage Breast Cancer Treatment

 
• By Andrew McConaghie

Already dominating in later lines of breast cancer treatment, Enhertu could now displace both chemotherapy combinations and Roche’s Kadcyla in early-stage HER2-positive patients.